浙江寿仙谷医药股份有限公司 关于召开2025年第二次临时股东会的通知

Group 1 - The company will hold its second extraordinary general meeting of shareholders in 2025 on December 23, 2025 [2][5] - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [3][6] - The company aims to enhance participation from small and medium investors by providing reminder services for the meeting [3][4] Group 2 - The company plans to provide a guarantee of 600 million RMB for its wholly-owned subsidiaries within a comprehensive credit limit for 2026 [20][21] - As of the announcement date, the actual guarantee balance provided to subsidiaries is 190 million RMB [21][26] - The company intends to apply for a total credit limit of up to 800 million RMB from various financial institutions [21][25] Group 3 - The company has decided to postpone the expected usable status date for two fundraising investment projects from November 30, 2025, to June 30, 2026 [29][36] - The postponement does not alter the total investment amount or construction scale of the projects [29][37] - The company emphasizes that the delay is a cautious decision based on market conditions and will not significantly impact its normal operations [37][39] Group 4 - The company has revised its remuneration management system for directors and senior management to align with current regulations and improve internal governance [42] - The revised system was approved during the sixth meeting of the fifth board of directors [42][41] Group 5 - The company plans to use up to 250 million RMB of temporarily idle fundraising and up to 1 billion RMB of idle self-owned funds for cash management in 2026 [55][56] - The investment will focus on low-risk financial products such as structured deposits and large certificates of deposit [58][64] - The decision to manage idle funds aims to enhance capital efficiency without affecting ongoing projects or normal operations [70][71]